Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02819999 |
| Title | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Stemcentrx |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |